50 results on '"Ishida T."'
Search Results
2. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
3. 1016P Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
4. 404P Real-world analysis on molecular targeted therapy recommendations and attainment rates in cancer gene panel testing for metastatic breast cancer
5. 359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study
6. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
7. 1040P Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
8. 497P Metastatic potential of the somatic alteration associated with TCA-cycle in breast cancer
9. 480P Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
10. CURRENT ISSUES ON CHEMOTHERAPY SERVICE OF HOSPITALS IN TOHOKU DISTRICT: RESULTS OF A QUESTIONNAIRE SURVEY
11. 328P Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial
12. 990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
13. O3–100 - Prognostic Impact of Central Nervous System Metastases and T790M Status After Acquired Resistance to EGFR-TKI
14. O3–089 - Continuation Maintenance Therapy with Pemetrexed(PEM) ± Bevacizumab(BEV) Following First Line Cisplatin/PEM ± BEV for NSCLC
15. O1–066 - A Multicenter Phase II Study of Mogamulizumab (KW-0761) in Patients with Relapsed Peripheral or Cutaneous T-Cell Lymphoma
16. Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
17. Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study
18. Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
19. A joint metabolic profile of plasma and tissue samples or discovering novel biomarkers in breast cancer
20. P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer
21. A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
22. Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer
23. Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
24. Molecular feature and clinical use development of gene expression profile “TP53 signature” in early stage breast cancer
25. 481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
26. 1514P - Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study
27. 1307P - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
28. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
29. 1893PD - A joint metabolic profile of plasma and tissue samples or discovering novel biomarkers in breast cancer
30. 30P - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer
31. 465P - A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
32. 1693P - Development of TP53 signature diagnostic system using multiplex RT-PCR and observational study to confirm the prognostic value of TP53 signature in breast cancer
33. 1000PD - Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses from the CHRONOS-1 study
34. 90P - Molecular feature and clinical use development of gene expression profile “TP53 signature” in early stage breast cancer
35. Final Result of Randomized Phase 2 Trial Comparing Amrubicin (A) with Re-Challenge of Platinum Doublet (P) in Patients (Pts) with Sensitive-Relapsed Small-Cell Lung Cancer (Sclc): Njlcg0702
36. Updated Data on Clinical and Molecular Profile of Surgically Resected Small Cell Lung Cancer: Intergroup Study with Fight002 and Hot1301
37. 1259P - Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
38. A Multicenter Phase II Study of Mogamulizumab (KW-0761) in Patients with Relapsed Peripheral or Cutaneous T-Cell Lymphoma
39. Continuation Maintenance Therapy with Pemetrexed(PEM) ± Bevacizumab(BEV) Following First Line Cisplatin/PEM ± BEV for NSCLC
40. Prognostic Impact of Central Nervous System Metastases and T790M Status After Acquired Resistance to EGFR-TKI
41. Phase II Trial of Carboplatin and Pemetrexed as First-Line Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer and Correlation between the Efficacy/Toxicity and Single Nucleotide Polymorphisms Associated with Pemetrexed Metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
42. Developing Prognostic Biomarker of Breast Cancer using Expression Profile about TP53 Status
43. Parental Cancer: Reviewing the Concerns of Breast Cancer Patients with Children
44. 1465P - Updated Data on Clinical and Molecular Profile of Surgically Resected Small Cell Lung Cancer: Intergroup Study with Fight002 and Hot1301
45. 1471P - Final Result of Randomized Phase 2 Trial Comparing Amrubicin (A) with Re-Challenge of Platinum Doublet (P) in Patients (Pts) with Sensitive-Relapsed Small-Cell Lung Cancer (Sclc): Njlcg0702
46. O3-052 - Current Issues on Chemotherapy Service of Hospitals in Tohoku District: Results of a Questionnaire Survey
47. O2-012 - Phase II Trial of Carboplatin and Pemetrexed as First-Line Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer and Correlation between the Efficacy/Toxicity and Single Nucleotide Polymorphisms Associated with Pemetrexed Metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902
48. WS9-7 - Developing Prognostic Biomarker of Breast Cancer using Expression Profile about TP53 Status
49. 1606P - Parental Cancer: Reviewing the Concerns of Breast Cancer Patients with Children
50. O18-5 Sacituzumab govitecan in Japanese patients with metastatic triple-negative breast cancer: phase 2 results of ASCENT J02.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.